Budget impact of oral semaglutide intensification versus sitagliptin among US patients with type 2 diabetes uncontrolled with metformin
mediaposted on 2020-11-05, 19:38 authored by Elizabeth Wehler, Dominik Lautsch, Stacey Kowal, Glenn Davies, Andrew Briggs, Qianyi Li, Swapnil Rajpathak, Adnan Alsumali
The above plain language summary and video abstract represent the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, please see the full text online (see “read the peer-reviewed publication” opposite).
© The authors, CC-BY-NC 2020.